Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

[1]  S. Halford,et al.  Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. , 2018 .

[2]  S. Sallan,et al.  A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry. , 2018 .

[3]  P. Ott,et al.  Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. , 2018 .

[4]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[5]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[6]  M. Perazella,et al.  Adverse kidney effects of epidermal growth factor receptor inhibitors , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Lutzky,et al.  Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor , 2017, Journal of Immunotherapy for Cancer.

[8]  K. Jhaveri,et al.  Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review , 2017, American Journal of Nephrology.

[9]  C. Robert,et al.  Renal effects of immune checkpoint inhibitors , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  J. Mazières,et al.  Acute interstitial nephritis related to immune checkpoint inhibitors , 2016, British Journal of Cancer.

[11]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[12]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[13]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yuzhang Wu,et al.  Expression of B7-H1 in Inflammatory Renal Tubular Epithelial Cells , 2005, Nephron Experimental Nephrology.

[15]  L. Glimcher,et al.  MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. , 1990, Kidney international.